// App-Quantinova.ai

7602 : Phase I trial of the hedgehog (Hh) inhibitor, LDE225, in combination with etoposide and cisplatin (EP) for initial treatment of extensive stage small cell lung cancer (ES-SCLC).

Researchers

Presenter

  • Maria Catherine Pietanza

Principal Investigators

  • Lee M. Krug

  • Anna M. Varghese

  • Anne Haughney-Siller

  • Dorothy Dulko

  • Grace Monger

  • Melanie Albano

  • Clare M Moran

  • Mark G. Kris

  • Andrei Holodny

  • Camelia S. Sima

  • Anna Maria Litvak

  • Kenneth K. Ng

  • Payal R. Patel

  • Fawzia Ibrahim

  • Charles M. Rudin

  • Martin Fleisher

  • Jerrold B. Teitcher

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Memorial Sloan-Kettering Cancer Center, New York, NYMemorial Sloan-Kettering Cancer Center, Tarrytown, NYMemorial Sloan Kettering Cancer Center, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Small cell lung cancer

  • Brain metastasis

  • Lung Cancer

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Etoposide

  • Etoposide phosphate

  • Cisplatin

  • Sonidegib

Outcome

  • Positive

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved